| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000026524 |
| Receipt No. | R000030418 |
| Official scientific title of the study | Effect of Daily Ingestion of High-Lycopene Tomato "PR-7" on Lipid Metabolism for 8 weeks: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group |
| Date of disclosure of the study information | 2017/03/13 |
| Last modified on | 2018/03/19 (Ver. 5) |
| Basic information | ||
| Official scientific title of the study | Effect of Daily Ingestion of High-Lycopene Tomato "PR-7" on Lipid Metabolism for 8 weeks: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group | |
| Title of the study (Brief title) | Beneficial Effects of High-Lycopene Tomato "PR-7" on Lipid Metabolism | |
| Region |
|
|
| Condition | ||
| Condition | Healthy adults | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To prove clinical benefits associated with 8 week daily ingestion of high-lycopene tomato "PR-7" on lipid metabolism. Additionally to examine anti-oxidant effects, reduction of VFA, improvement of glucose metabolism, and anti-fatigue effects in order to evaluate the comprehensive effects of high-lycopene tomato "PR-7" for health promotion and health maintenance. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | |
| Assessment | |
| Primary outcomes | TC, LDL-C, HDL-C, TG, LDL-C/HDL-C, and non-HDL at 4 and 8 weeks after beginning the ingestion of test food. |
| Key secondary outcomes | serum lycopene, serum alpha-carotene, serum beta-carotene, serum vitamin A, MDA-LDL, serum-LPO, urinary isoprostane, urinary HEL, LOX-index, sLOX-1, LAB, visceral fat area (using impedance methods), abdominal subcutaneous fat area (using impedance methods), abdominal fat area (using impedance methods), body weight, body fat percentage, BMI, waist, FPG, HbA1c, blood pressure, POMS 2 full-length versions for adults, VAS questionnaire assessed fatigue, stress etc. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | YES |
| Dynamic allocation | NO |
| Institution consideration | |
| Blocking | YES |
| Concealment | No need to know |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Daily ingestion of 50 g semi-dried tomato of high-lycopene tomato "PR-7" for 8 weeks. | |
| Interventions/Control_2 | Daily ingestion of 50 g semi-dried tomato of placebo tomato (lycopene-free tomato) for 8 weeks. | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Subjects whose LDL-C is >=120 mg/dl and <160 mg/dl.
2. Subjects who agree to participate in this study with a written informed consent. |
|||
| Key exclusion criteria | 1. Subjects who are under physician's advice, treatment, and/or medication for dyslipidemia, diabetes, and/or obesity.
2. Subjects whose BMI is >=30 kg/m2. 3. Subjects with familial hypercholesterolemia. 4. Subjects with serious cerebrovascular, cardiac, hepatic, renal, gastrointestinal diseases, and/or affected with infectious diseases requiring reports to the authorities. 5. Subjects with major surgical history relevant to the digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc. 6. Subjects with unusually high and/or low blood pressure and/or abnormal hematological data. 7. Subjects with severe anemia. 8. Pre- or post-menopausal women complaining of obvious physical changes. 9. Subjects who are at risk of having allergic reactions to drugs or foods especially based on tomato, Japanese cedar, Japanese cypress, or grass. 10. Subjects who regularly take medicine, functional foods, and/or supplements which would affect blood lipid levels. 11. Subjects who regularly take medicine, functional foods, and/or supplements which would affect glucose metabolism. 12. Subjects who regularly take drugs, functional foods, and/or supplements which would affect BW and BFP. 13. Smokers. 14. Alcohol addicts or subjects with eating disordered lifestyle. 15. Subjects who donated either 400 ml whole blood within 16 weeks (women), 12 weeks (men), 200 ml whole blood within 4 weeks (men and women), or blood components within 2 weeks (men and women), prior to the current study. 16. Pregnant or lactating women or women who expect to be pregnant during this study. 17. Subjects who currently participate in other clinical trials, or participated within the last 4 weeks prior to the current study. 18. Any other medical and/or health reasons unfavorable to participation in the current study, as judged by the principal investigator. |
|||
| Target sample size | 26 | |||
| Research contact person | |
| Name of lead principal investigator | Prof. Jun NISHIHIRA, M.D., Ph.D. |
| Organization | Hokkaido Information University |
| Division name | Department of Medical Management and Informatics |
| Address | 59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan |
| TEL | 011-385-4411 |
| nishihira@do-johodai.ac.jp | |
| Public contact | |
| Name of contact person | Dir. Prof. Jun NISHIHIRA, M.D., Ph.D. |
| Organization | Hokkaido Information University |
| Division name | Health Information Science Center |
| Address | 59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan |
| TEL | 011-385-4430 |
| Homepage URL | |
| nishihira@do-johodai.ac.jp | |
| Sponsor | |
| Institute | Hokkaido Information University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | NARO Bio-oriented Technology Research Advancement Institution |
| Organization | |
| Division | |
| Category of Funding Organization | Japanese Governmental office |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | TAKII & COMPANY, LIMITED |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 北海道情報大学 保健センター(北海道) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030418 |